Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line

Cancer Research

Volumn 70, Issue 16, 2010, Pages 6587-6597

  Chen, Rong ^a   Chubb, Sherri ^a   Cheng, Tiewei ^b   Hawtin, Rachael E ^c   Gandhi, Varsha ^a,b   Plunkett, William ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Sunesis Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; ONCOPROTEIN; PROTEIN MCL 1; SMALL INTERFERING RNA; CCND1 PROTEIN, HUMAN; MYELOID LEUKEMIA FACTOR 1; N-(5-(((5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL)METHYL)THIO)-2-THIAZOLYL)-4-PIPERIDINECARBOXAMIDE; OXAZOLE DERIVATIVE; PROTEIN BCL 2; RNA; SMALL NUCLEAR RNA; THIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA SYNTHESIS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL GROWTH; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; LYMPHOMA, MANTLE-CELL; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL CYCLE; CELL DEATH; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN D1; HUMANS; LYMPHOMA, MANTLE-CELL; OXAZOLES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, NEOPLASM; RNA, SMALL NUCLEAR; THIAZOLES; TRANSFECTION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN;

EID: 77955720554     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3578     Document Type: Article

References (40)

1. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-62. (Pubitemid 47463673)
2. Smith MR. Mantle cell lymphoma: advances in biology and therapy. Curr Opin Hematol 2008;15:415-21.
3. Williams ME, Densmore JJ. Biology and therapy of mantle cell lymphoma. Curr Opin Oncol 2005;17:425-31.
4. Conroy A, Stockett DE, Walker D, et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 2009;64:723-32.
5. Chen R, Wierda WG, Chubb S, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009;113:4637-45.
6. Tong WG, Chen R, Plunkett W, et al. Phase I study of SNS-032, a potent and specific Cdk2, 7 and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). J Clin Oncol 2010;28:3015-22.
7. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008;26:59-65.
8. Rimokh R, Berger F, Bastard C, et al. Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood 1994;83:3689-96. (Pubitemid 24175560)
9. Amin HM, McDonnell TJ, Medeiros LJ, et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 2003;127:424-31.
10. Dennison JB, Balakrishnan K, Gandhi V. Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis. Br J Haematol 2009;147:297-307.
11. Romano P, Manniello A, Aresu O, Armento M, Cesaro M, Parodi B. Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines. Nucleic Acids Res 2009;37:D925-32.
12. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006;66:10959-66. (Pubitemid 44876995)
13. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005;106:2513-9. (Pubitemid 41510827)
14. Tagawa H, Karnan S, Suzuki R, et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005;24:1348-58. (Pubitemid 40343115)
15. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-64. (Pubitemid 43053550)
16. Tan X, Wang JY. The caspase-RB connection in cell death. Trends Cell Biol 1998;8:116-20.
17. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006;6:493-505.
18. Venkataraman G, Maududi T, Ozpuyan F, et al. Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment. Leuk Res 2006;30:1377-84. (Pubitemid 44307323)
19. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994;13:2124-30.
20. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 1994;13:3487-95. (Pubitemid 24246185)
21. Klier M, Anastasov N, Hermann A, et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008;22:2097-105.
22. Khoury JD, Medeiros LJ, Rassidakis GZ, McDonnell TJ, Abruzzo LV, Lai R. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol 2003;199:90-7. (Pubitemid 36054733)
23. Jeon HJ, Kim CW, Yoshino T, Akagi T. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol 1998;102:1323-6. (Pubitemid 28435219)
24. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-68.
25. Rudolph C, Steinemann D, Von Neuhoff N, et al. Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519. Cancer Genet Cytogenet 2004;153:144-50. (Pubitemid 39592147)
26. Pscherer A, Schliwka J, Wildenberger K, et al. Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphoma. FASEB J 2006;20:1188-90.
27. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001;38:139-70.
28. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527-36. (Pubitemid 27060443)
29. Lacrima K, Valentini A, Lambertini C, et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 2005;16:1169-76.
30. Schubert KM, Duronio V. Distinct roles for extracellular-signal-regulated protein kinase (ERK) mitogen-activated protein kinases and phosphatidylinositol 3-kinase in the regulation of Mcl-1 synthesis. Biochem J 2001;356:473-80. (Pubitemid 32532358)
31. Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 1995;128:1173-84.
32. Carlson B, Lahusen T, Singh S, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999;59:4634-41. (Pubitemid 29428969)
33. Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, BCMA. Mol Cancer Ther 2007;6:460-70.
34. Gurel G, Blaha G, Moore PB, Steitz TA. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol 2009;389:146-56.
35. Meng H, Yang C, Jin J, Zhou Y, Qian W. Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Leuk Lymphoma 2008;49:1954-62.
36. Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 2005;90:1433-4. (Pubitemid 41503659)
37. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007;21:333-9. (Pubitemid 46158128)
38. Ansell SM, Inwards DJ, Rowland KM, Jr., et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008;113:508-14.
39. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009;16:36-43.
40. Chen R, Plunkett W. Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010;23:155-66.